All In Biotech

Free tool

FAERS Monitor: Avycaz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206494 or its brand name (Avycaz, Avibactam Sodium, Ceftazidime). Reports on generic versions are filed under their own applications.

Reports

169

Serious

72

43% of reports

Hospitalization

33

Death reported

16

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use34
  • product storage error15
  • drug resistance12
  • respiratory failure9
  • acute kidney injury8
  • hypotension7
  • mental status changes7
  • pyrexia7
  • death6
  • dyspnoea6
  • headache6
  • nausea6
  • drug ineffective5
  • pneumonia5
  • abdominal pain4

Reports by year received

View as table
YearReports
201515
201622
201719
201811
201926
202014
202111
202210
20234
20248
202514
202615

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,990 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug resistanceSignal1258.233.7619
mental status changesSignal731.415.2177
product storage errorSignal1521.313.2272
respiratory failureSignal915.48.1107
acute kidney injurySignal86.53.332
off label useSignal344.83.6104
hypotensionSignal74.32.115
pyrexiaSignal72.51.25
abdominal pain42.10.81
pneumonia51.90.81
dyspnoea61.30.60
headache61.20.50
nausea60.90.40
death60.90.40
drug ineffective50.50.23

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.